Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.59 |
| ▸ | LMNA | P02545 | 3/20 | 0.59 |
| ▸ | HPGD | P15428 | 1/20 | 0.59 |
| ▸ | PIKFYVE | Q9Y2I7 | 7/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.48 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.48 |
| ▸ | SENP7 | Q9BQF6 | 1/20 | 0.48 |
| ▸ | SENP6 | Q9GZR1 | 1/20 | 0.48 |
| ▸ | GBA1 | P04062 | 1/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL912360 | 0.84 | KDM4E (0.70) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL912362 | 0.84 | KDM4E (0.70) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL912259 | 0.81 | KMT2A (0.48) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL12903015 | 0.81 | KMT2A (0.48) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL12903005 | 0.80 | KDM4E (0.72) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL913111 | 0.80 | KDM4E (0.72) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL913109 | 0.80 | KDM4E (0.72) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL913770 | 0.78 | KDM4E (0.59) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL23318021 | 0.77 | MAPT (0.60) | KDM4EMAPTLMNAHPGDPIKFYVE | |
| SCHEMBL426265 | 0.76 | PIKFYVE (0.75) | KDM4EMAPTLMNAHPGDPIKFYVE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7872005-B2 | 2-substituted heteroaryl compounds | SYNTA PHARMACEUTICALS CORPORATION (US) | 2011-01-18 | — | — | US | disclosed |
| US-20060063739-A1 | 2-Substituted heteroaryl compounds | LSI FINANCING LLC, AS ADMINISTRATIVE AGENT | 2006-03-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063739-A1 | 2-Substituted heteroaryl compounds | IL2, IL4, IL2RA | KDM4E 4142/4885MAPT 1171/4885LMNA 4190/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.